FDA Encourages Bovine Heparin Reintroduction to Diversify Porcine-Dependent Supply Chain

Supply chain vulnerability in the heparin market is driving FDA to actively encourage manufacturers to reintroduce bovine-sourced heparin, signaling a formal shift in agency posture after decades of near-total reliance on porcine raw material. For plant heads and QA directors currently sourcing heparin API, the guidance reframes bovine origin not as a legacy risk but as a viable diversification pathway.

Bovine lung heparin held US market approval from the 1930s until the late 1990s, when manufacturers voluntarily withdrew it following concerns over transmissible spongiform encephalopathy (TSE) contamination risk. Porcine heparin filled the gap, but the 2008 discovery of Over-Sulfated Chondroitin Sulfate (OSCS) contamination in porcine supply exposed the fragility of a single-source dependency. Bovine mucosal heparin has since remained in active commercial use in Brazil and Argentina, accumulating a safety record that FDA now cites as part of its rationale for re-engagement.

FDA's current position is that sponsors should initiate contact through the pre-IND process, submitting a comprehensive meeting package before formal application. The required package scope is specific: manufacturer identity and address, candidate product description including biological source, dosage form details, quantitative composition, CMC information scaled to development stage per 21 CFR 312.23(a)(7)(i), test methods with certificates of analysis, excipient grades, and method-of-manufacture summaries with available stability data.

For regulatory affairs leads, the CMC expectations are deliberately staged. The agency's reference to 21 CFR 312.23(a)(7)(i) confirms that CMC depth should be commensurate with development phase, reducing the barrier to early-stage pre-IND engagement. CDER has indicated it will consider meeting requests to discuss safety, efficacy, quality, and purity on a case-by-case basis, which gives sponsors a structured channel to pressure-test their dossier assumptions before committing to full IND preparation.

CGMP compliance and raw material traceability remain non-negotiable conditions. FDA's guidance reiterates that manufacturers must implement controls sufficient for source verification, process monitoring, and quality assurance across the supply chain, consistent with existing animal-sourced product expectations under current good manufacturing practice frameworks.

The measurable near-term checkpoint is pre-IND meeting request volume, which will indicate how quickly the industry moves to convert FDA's stated openness into active development programs.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Drugs RSS Feed, June 5, 2026.